Mission

 

BEST VENTURE INVESTMENT EXPERTISE IN PHARMACEUTICALS AND LIFE SCIENCES

Creating world-class Russian-domiciled expertise in the field of venture capital financing in the medical, pharmaceutical and biotechnology sectors;

UNIQUE PORTFOLIO OF INNOVATIONS

Localization in Russia of the world’s most promising and advanced innovative medicines and associated technologies through acquisition/in-licensing of the intellectual property rights for Russia of the companies in which RusnanoMedInvest takes an investment stake

CONTRIBUTION TO THE DEVELOPMENT OF THE RUSSIAN PHARMACEUTICALS AND LIFE SCIENCES INDUSTRIES

Significant contribution to the modernization of the Russian pharmaceutical industry and its integration with international leaders in medicine and pharmaceuticals, including the largest investment funds, pharmaceutical companies and research centers in order to proactively facilitate the integration of the emerging Russian life sciences innovation clusters into theglobal innovation value chains in life sciences and associated industries

SIGNIFICANT BENEFITS FOR RUSSIAN SOCIETY OVERALL

The fund has set itself a clear objective of generating increased interest from the  Russian investment community in venture capital investments in both Russian and international companies and other new ventures in the field of Life Sciences.

Leonid Melamed

Member of the Board of Directors 
RosnanoMedInvest 

 

 

"It is intended that the successful investments and technology transfer arrangements arising out of the portfolio activity of RusnanoMedInvest will significantly reduce the introduction lead time of the best of any new  and innovative medicines and medical devices onto the Russian market. For Russian consumers, this means that they will, in effect, gain access to the world’s most advanced medicines at the same time as these products are launched in mature markets around the world. We believe that this accelerated-availability program for new, highly innovative and venture-funded medical treatments will, equally, represent a major step forward in “raising the bar” and setting a compelling demonstration-effect example for the nascent Russian life sciences venture capital community in terms of the standards it needs to reach to become globally competitive."

 

 


 

 

All Partners

All Portfolio

MEDIA CENTER

  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news